Stuart Therapeutics
Stuart
About Stuart Therapeutics
Stuart Therapeutics is a biotechnology company that offers PolyCol, a therapeutic platform for ophthalmic indications. PolyCol’s unique method of action results in accelerated healing and recovery in various ophthalmic disease states and offers a new way to address indications such as dry eye disease, dry age related macular degeneration, and glaucoma. PolyCol is based on patented research from a major U.S. university, combined with additional intellectual property acquired by Stuart Therapeutics. The company has developed applications for PolyCol in treating certain ophthalmic, gastrointestinal, inflammatory, and oncology conditions.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $11.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Mar 2021)
- Website: stuarttherapeutics.com
- Phone: (772) 678-7307
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/stuart-therapeutics-82304 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.